ABSTRACT
Objective To analyze the expression and clinical significance of exonucleotide pyro-phosphatase/phosphodiesterase family member 2 (ENPP2) in acute myeloid leukemia (AML), and to ex-plore its potential molecular mechanism. Methods The expression profiles of ENPP2 in different normal tissues was analyzed with GTEx database. Rstudio and Graphpad were used to analyze ENPP2 expression, genomic mutations and survival curve in data from GEO and TCGA databases, and the signaling pathway as-sociated with ENPP2 expression were further analyzed with GSEA enrichment software. Results In normal tissues, ENPP2 was mainly expressed in fat, brain and uterus;the expression in acute myeloid leukemia tis-sues was higher than that in donors. Only 0. 5％ of patients in 187 TCGA genomic data had gene amplifica-tion, there was no gene mutations and deletions. ENPP2 expression in recurrent AML was significantly high-er than primary patients, and its high expression was associated with poor prognosis. Gene enrichment anal-ysis shows high ENPP2 group isenriched in autoimmune diseases, cytokine receptor activation pathway, and low ENPP2 was enriched in DNA replication, cell cycle pathways. ENPP2 was also involved in the pathway that associated with retinoic acid and glucocorticoids treatment. Conclusions ENPP2 is highly expressed in AML patients and is associated with recurrence and poor prognosis of AML. The main molecular mecha-nism of ENPP2 in AML may be related to autoimmune response and drug treatment response, ENPP2 is a potential therapy target of AML.